-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $455

Benzinga·07/16/2026 12:02:09
语音播报
Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $399 to $455.